About MetriTrack
Our Story
As a breast radiologist with many years of experience, Dr. Calin Caluser witnessed firsthand the frustrations of inconsistent, non‑standardized ultrasound exams, gaps that can delay lifesaving detection and lead to missed or misdiagnosed small cancers. Frustrated by the absence of a reliable solution, he set out to build a system that empowers any user, anywhere, to conduct consistently high‑quality diagnostic and screening breast ultrasounds.
Together with a handful of engineers and scientists, he founded MetriTrack, secured multiple patents, and advanced research to overcome the shortcomings of traditional hand-held breast ultrasound techniques.
Our mission is simple: to save lives through earlier, more accurate detection and treatment of breast cancer. We’re committed to delivering a tool that benefits patients, physicians, and technologists alike.
Company Snapshot
MetriTrack, Inc. is a privately owned medical device technology company focused on advancing the current state of breast cancer care. We provide automated solutions for breast ultrasound. Our innovations are designed to find more breast cancers, faster and at lower cost than possible today.
Management Team
Calin Caluser
MD, Founder, & CEOEntrepreneur and Board-certified radiologist with over 20 years of experience in breast imaging , patent author, former Chief of Breast Imaging at Cook County Hospital/Chicago.
Michael Cannizzaro
Chairman of the Board of DirectorsFormer CEO, Chairman of the Board or director with Caremark Intl., Beltone, Sunrise Medical and more.
Mirela Wohlford
Principal Quality and Regulatory Compliance SpecialistExpert in leading and executing regulatory compliance strategies for medical device startup companies.
Guang Yang
Lead Software EngineerBrings significant knowledge and experience in prototyping, design, development and maintaining medical imaging pipelines; productizing image processing algorithms using parallel computing technologies.
Advisory Team
MetriTrack is privileged to partner with radiology and business experts who comprise our advisory board. Each advisor shares our commitment to helping more women survive breast cancer. Their counsel will continue to contribute to our R&D and Commercialization plans, enabling us to bring our novel technology system to providers and patients worldwide.